Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Crystal Structures Define Mode of Action of Bacteriophage Endolysins

By LabMedica International staff writers
Posted on 13 Aug 2014
New antibacterial agents based on bacteriophages or their endolysin enzymes have been proposed to solve the problem of the bacterium Clostridium difficile, which is becoming a serious health hazard in hospitals and healthcare institutes, due to its resistance to antibiotics.

Investigators at the European Molecular Biology Laboratory (Hamburg, Germany) based their research primarily on the bacteriophage CD27, which is capable of lysing C. More...
difficile. In addition, they worked with a recombinant form of the CD27L endolysin, which lyses C. difficile in vitro.

To better understand how the lysis process works, the investigators determined the three-dimensional structures of the CD27L endolysin and the CTP1L endolysin from the closely related bacteriophage CPT1 that targets C. tyrobutyricum. For this task they employed X-ray crystallography and small angle X-ray scattering (SAXS), which was done at the Deutsches Elektronen-Synchrotron (DESY).

Results published in the July 24, 2014, online edition of the journal PLOS Pathogens revealed that the two endolysins shared a common activation mechanism, despite having been taken from different species of Clostridium. The activation mechanism depended on a structure where an extended dimer existed in the inactive state but switched to a side-by-side "relaxed" morphology in the active state, which triggered the cleavage of the C-terminal domain. This change of morphology led to the release of the catalytic portion of the endolysin, enabling the efficient digestion of the bacterial cell wall.

“These enzymes appear to switch from a tense, elongated shape, where a pair of endolysins is joined together, to a relaxed state where the two endolysins lie side-by-side,” said first author Dr. Matthew Dunne, a researcher at the European Molecular Biology Laboratory. “The switch from one conformation to the other releases the active enzyme, which then begins to degrade the cell wall.”

Related Links:

European Molecular Biology Laboratory



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.